board of directors

Jeff Lucero Riley, M.B.A.

Mr. Riley has more than 20 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in, venture financings to support product development (in excess of $2B). Currently, Mr. Riley is Managing Director of 526 Ventures, a boutique life sciences-focused investment bank. Prior to this, he was President of an ASX-listed SPAC (Special Purpose Acquisition Company) and was responsible for identifying and acquiring appropriate assets to repurpose the entity. He sits on the advisory boards of an Australia-based venture fund (Queensland Biocapital Fund), Ruga, a Bay area-based drug discovery company and HUYA (Shanghai-based biotechnology company). Mr. Riley has held senior “C” level corporate and commercial development positions with Amphora Discovery, Ontogen Corporation, AvMax Inc., and several start-ups. In these positions, he was responsible for raising equity and negotiating significant alliances including in/out licenses, distributions agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. Riley's pharmaceutical and financial industry experience includes commercial management and M&A roles in Europe and Latin America for Nichols Institute (A Division of Quest Diagnostics, Inc. NASDAQ:DGX); Pfizer Pharmaceuticals, Inc.; SmithKline Beecham Plc.; and Citibank-Brazil. He has lived and worked in Venezuela, Brazil, Turkey, South Africa, and The Netherlands. Riley’s education includes: B.S. International Relations, B.S. Biology (Boise State), coursework at UCSF/Berkeley in drug discovery/development and participated in a dual-degree graduate program, M.B.A./M.I.M., sponsored by Arizona State University and the American Graduate School of International Management (Thunderbird).

Steve H. Kanzer, C.P.A., Esq.

Mr. Kanzer is our co-founder of Adeona and served as our President from our inception in February 2001 until May 2006. From September 2004 through July 2008, Mr. Kanzer also served as Chairman and Chief Executive Officer. Mr. Kanzer has also been a director and officer of our subsidiaries, including Solovax, Inc., Effective Pharmaceuticals, Inc., Putney Drug Corp. and CD4 Biosciences, Inc. Since December 2000, he has served as co-founder and Chairman of Accredited Ventures Inc. and Accredited Equities Inc., a venture capital firm and FINRA-member investment bank, respectively, which both specialize in the biotechnology industry. Mr. Kanzer was co-founder, Chairman, President and Chief Executive Officer of Developmental Therapeutics, Inc., a cardiovascular drug development company which was developing an oral thyroid hormone analog, DITPA, for congestive heart failure. Developmental Therapeutics was acquired in October 2003 by Titan Pharmaceuticals, Inc., a publicly traded biopharmaceutical company.

Jeffrey J. Kraws, M.B.A.

Mr. Kraws is Chief Executive Officer and co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a “5-Star Rating” in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an M.B.A. from Cornell University and a B.S. degree from State University of New York-Buffalo.

James S. Kuo, M.D., M.B.A.

Since February 2007, Dr. Kuo has served Adeona as a member of the Company’s board of directors. In February 2010, Adeona’s board appointed him as Chief Executive Officer and President. He also served as Adeona’s Chairman from February 2010 to November 2011. Previously, Dr. Kuo was Chairman and Chief Executive Officer of Cordex Pharma, a publicly-traded enterprise developing a portfolio of cardiovascular drugs. He launched life science products as Chairman and Chief Executive Officer of BioMicro Systems, a genomic tools company. At Discovery Laboratories, a publicly-traded company developing new surfactant-based respiratory therapeutics, he was a founder and Chief Executive Officer. Dr. Kuo is a founder and board director of Monarch Labs, a privately-held company commercializing medical devices for wound care. He held positions as a licensing executive at Pfizer and Vice President of Business Development at Myriad Genetics. Dr. Kuo was a Managing Director of Venture Analysis with HealthCare Ventures, a venture capital firm with $378 million in funds under management. He served as Chairman of the board of Soligenix, a publicly-traded enterprise developing therapeutic for the life-threatening side effects of cancer therapy and vaccines for certain bioterrorism agents. Currently, he serves as Non-executive Chairman of the board of MSK Pharma, a privately-held company clinically developing Xiaderma, a topical patch to treat carpal tunnel syndrome. Dr. Kuo simultaneously earned an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School of Business. He holds a B.A. in molecular biology from Haverford College.

Jeffrey Wolf, M.B.A., Esq.

Mr. Wolf has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture capital group focused on seed-stage technology-based investments. Mr. Wolf has been a founder of Elusys Therapeutics, Inc., an antibody-based therapeutic company, Tyrx Pharma, Inc., a biopolymer-based company, Sensatex, Inc., a medical device company and Generation Mobile, Inc. a telecommunications company. Prior to founding Seed-One Ventures, Mr. Wolf served as the Managing Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was responsible for supervising the formation and funding of new technology, biomedical, and service oriented ventures. Mr. Wolf currently sits on the board of Elusys Therapeutics and Netli, Inc. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. with honors in Economics from the University of Chicago.